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Generic productsAbstract Dissolution proﬁles of four carbamazepine immediate-release generic products (200 mg
tablets) and the reference product Tegretol were evaluated using the USP paddles method and
an alternative method with the ﬂow-through cell system, USP Apparatus 4. Under ofﬁcial condi-
tions all products met the Q speciﬁcation, dissolution proﬁles of generic products were similar to
the dissolution proﬁle of the reference product (f2 > 50) and model-independent parameters
showed non signiﬁcant differences to the reference product except mean dissolution time for prod-
uct A (p< 0.05). On the other hand, when the ﬂow-through cell system was used, none of the prod-
ucts met the pharmacopeial speciﬁcation at 15 min and product A did not reach dissolution criteria
at 60 min, dissolution proﬁles of all generic products were not similar to the reference product pro-
ﬁle (f2 < 50) and all model-independent parameters showed signiﬁcant differences compared to the
reference product (p< 0.05). Weibull’s model was more useful for adjusting the dissolution data of
all products in both USP apparatuses and Td values showed signiﬁcant differences compared to the
reference product (p< 0.05) when USP Apparatus 4 was used. These results indicate that the pro-
posed method, using the ﬂow-through cell system, is more discriminative in evaluating both, rate
and extent of carbamazepine dissolution process from immediate-release generic products.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
In the development of a new formulation or as a measure of
batch-to-batch quality control, the evaluation of rate and ex-
tent of dissolution of an active compound in a pharmaceutical
dosage form is elemental. For generic products, the quality of
excipients and the manufacturing process must allow full and
timely release of the drug in the same way as the reference
product does at predeﬁned conditions. An adequate release
evaluation of generic drugs promotes interchangeability of
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with the beneﬁt of a lower cost to the patient (Gidal and
Tomson, 2008). Carbamazepine is a narrow therapeutic index
drug that is widely used to treat epilepsy and other neurolog-
ical disorders and is marketed as immediate-release generic
products. Dissolution test for carbamazepine tablets is de-
scribed in the United States Pharmacopeia (USP 30, 2007).
The method indicates the use of USP Apparatus 2 (paddles)
at 75 rpm and 900 ml of 1.0% sodium lauryl sulfate aqueous
solution at 37.0 ± 0.5 C as dissolution medium. Under these
conditions and for products labeled as 200 mg tablets there are
two tests with the following times and tolerances: Test 2 be-
tween 45% and 75% of the labeled amount of carbamazepine
is dissolved in 15 min; not less than 75% (Q) of the labeled
amount of carbamazepine is dissolved in 60 min and Test 3 be-
tween 60% and 85% of the labeled amount of carbamazepine
is dissolved in 15 min; not less than 75% (Q) of the labeled
amount of carbamazepine is dissolved in 60 min.
The Biopharmaceutics Classiﬁcation System groups drugs
into four classes (Amidon et al., 1995). Carbamazepine belongs
to Class II (low solubility/high permeability), and its absorp-
tion in the gastrointestinal tract might be limited by the disso-
lution rate (Lindenberg et al., 2004). Compounds belonging to
Class II are eligible to establish a signiﬁcant in vitro/in vivo cor-
relation (IVIVC), hence the appropriate selection for dissolu-
tion study’s conditions is essential to have a method able to
discriminate between products with potential problems of bio-
availability. The establishment of a signiﬁcant IVIVC provides
the basis for estimating in vivo performance predictions and
waives the costly bioequivalence studies (FDA, 1999). Previous
reports mentioned signiﬁcant differences in dissolution proﬁles
of carbamazepine commercial products (Lake et al.,1999; Mit-
tapalli et al., 2008; Volonte´ et al., 2004), even within a single
brand (Davidson, 1995); in plasma levels of healthy volunteers
(Meyer et al., 1992) and in serum levels of patients undergoing
therapy with this drug (Rentmeester et al., 1990) as well as loss
of seizure control when one product is exchanged for another
(Olling et al., 1999). Lack of correlation between in vitro disso-
lution data using the USP ofﬁcial method and in vivo data was
also reported (Castro and Jung, 2000; Jung et al., 1997).
Since the introduction of the ﬂow-through cell system (USP
Apparatus 4), it was presented as an alternative dissolution
apparatus to the conventional vessels methods USP Apparatus
1 and 2 because of several advantages over traditional dissolu-
tion systems (Chevalier et al., 2009; Greco et al., 2011; Shiko
et al., 2011). The USP Apparatus 4 has a continuous extraction
of the drug, simulating the absorption into the systemic circu-
lation, generating intermittent ﬂow of dissolution medium into
the cell where the dosage form is placed (Qureshi et al., 1994).
It is possible to use it as an open system that can work under
sink conditions which facilitates the dissolution of poorly sol-
uble drugs as well as changing the dissolution medium within
a range of physiological pH values throughout the test (Zhang
et al., 1994). Prior information shows that in vitro dissolution
data obtained with the ﬂow-through cell system better reﬂect
the in vivo performance of some poorly soluble drugs (Jinno
et al., 2008; Okumu et al., 2008). The ﬂow-through cell system
has proved to be useful in the development of a more discrim-
inating dissolution method than the ofﬁcial one in the USP
Apparatus 2 for the poorly soluble compound albendazole
(Hurtado et al., 2003) and to establish an in vitro/in vivo rela-
tionship for paracetamol suppositories, a Class IV drug (Med-ina et al., 2009). Despite the advantages of the ﬂow-through
cell system over the USP Apparatus 1 and 2 information of
the dissolution of carbamazepine immediate-release oral dos-
age forms under USP Apparatus 4 is scarce (Bønløkke et al.,
1999).
The objective of this study was to evaluate the dissolution
characteristics of four carbamazepine generic products sold
in the local market and the reference product Tegretol under
the hydrodynamic environment generated by the ﬂow-through
cell system and to compare it with the results obtained with the
USP paddles method.2. Materials and methods
2.1. Materials
Five carbamazepine commercial products (200 mg) were used
in this study. Generic products (codiﬁed as: A, B, C and D
products) were compared with Tegretol as the reference
product (codiﬁed as: R product). Sodium lauryl sulfate was
purchased from Distribuidora Quı´mica Lufra-Me´xico. Car-
bamazepine standard was purchased from Sigma–Aldrich
Co. (St. Louis MO, USA).
2.2. Content uniformity and assay
Content uniformity and assay tests were performed with all
products, according to the procedures described in the United
States Pharmacopeia (USP 30, 2007).
2.3. Analytical method validation
The analytical method used was validated according to Mexi-
can regulations (Norma Oﬁcial Mexicana, 1999). To demon-
strate the linearity of the spectrophotometric system, six
calibration curves with ﬁve different carbamazepine concentra-
tions (range 2.5–20 lg/ml) prepared in the dissolution medium
(1.0% sodium lauryl sulfate aqueous solution) were analyzed
at 285 nm. Data obtained were ﬁtted by linear regression
and the coefﬁcients of regression, regression analysis of vari-
ance (ANOVA) and 95% conﬁdence interval (CI95%) for the
value of the intercept were calculated. The system precision
was demonstrated by calculating the percentage coefﬁcients
of variation (CV%) at each concentration level.
The method linearity (drug with excipients) was determined
by the added standard method by separately dissolving, in
900 ml of dissolution medium, quantities of powder from all
products equivalent to 20, 40, 60, 80, 100 and 120% of car-
bamazepine dose plus seven mg of carbamazepine standard
in each vessel. The USP Apparatus 2 at 75 rpm was used. At
60 min the amount of carbamazepine dissolved in each sample
was calculated with reference to a calibration curve prepared
on the day of the experiment. Each determination was per-
formed in triplicate. In order to evaluate the linearity of the
method, data were plotted (dissolved amount vs added
amount) and determination coefﬁcient (R2), CI95% for the
slope and intercept and regression ANOVA was calculated.
The accuracy was evaluated by calculating the CI95% of the
average percentage of carbamazepine recovered from the
known added amount of the drug. The precision was
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drug dissolved (repeatability). To evaluate the random events
effect on the analytical method precision a homogeneous sam-
ple of tablets powder, equivalent to 50% of the dose plus
10 mg of carbamazepine standard was analyzed in triplicate,
by two analysts in two different days (reproducibility); results
obtained were analyzed by a two-way ANOVA. Differences
were considered signiﬁcant if p< 0.05.
2.4. USP paddles method (pharmacopeial method)
Carbamazepine dissolution proﬁles were determined according
to the United States Pharmacopeia (USP 30, 2007) in an auto-
mated dissolution USP Apparatus 2 (Vankel VK 7000, Erweka,
Germany) with an auto-controlled multi-channel peristaltic
pump (Vankel VK 810, England), an UV/VIS spectrophotom-
eter (Varian Cary 50 Tablet, USA) with 1 mm ﬂow cells and
Vankel software. Carbamazepine intact tablets were added on
900 ml of 1.0% sodium lauryl sulfate aqueous solution as disso-
lution medium at 37.0 ± 0.5 C. Rotational speed of 75 rpm
was tested. Sequential sampling using ﬁlter probes occurred
over 60 min at regular ﬁve min intervals using 12 replicates.
The amount of carbamazepine dissolved was determined with
a known concentration of the standard solution at 285 nm.
2.5. Flow-through cell system (USP Apparatus 4)
Carbamazepine dissolution proﬁles were obtained with an
automated ﬂow-through cell system, USP Apparatus 4 (Sotax
CE6, Sotax AG, Switzerland) with 22.6 mm cells (i.d.) and a
piston pump (Sotax CY7–50, Sotax AG, Switzerland). In all
experiments laminar ﬂow (with a bed of 6 g of glass beads)
was used. The degassed dissolution medium, 1.0% sodium lau-
ryl sulfate aqueous solution at 37.0 ± 0.5 C, was pumped at a
ﬂow rate of 16 ml/min. An open system was used, without
recycling the dissolution media. Sequential sampling using
0.45 lm nitrocellulose membranes (Millipore) occurred over
60 min at regular ﬁve min intervals using 12 replicates. The
amount of carbamazepine dissolved was determined in an
UV/VIS spectrophotometer (Perkin Elmer Lambda 10, USA)
with 1 mm ﬂow cells at 285 nm. For every trial, a standard
curve was prepared.
2.6. Data analysis
Dissolution proﬁles of generic products (both apparatuses)
were compared to dissolution proﬁle of the reference product
using f2 similarity factor according to Eq. (1) (Moore and
Flanner, 1996).
f2 ¼ 50 log 1þ 1
n
 Xn
j¼1
jRj  Tjj2
" #0:5
 100
8<
:
9=
; ð1Þ
where n is the number of time points used to evaluate the
amount of carbamazepine dissolved, Rj and Tj are the average
percentage of carbamazepine dissolved at a j speciﬁc time from
the reference and test products, respectively.
Additionally, carbamazepine dissolution data of each prod-
uct were used to calculate model-independent parameters:
mean dissolution time (MDT) (Podczeck, 1993) and dissolu-
tion efﬁciency (DE) (Khan, 1975). Generic products valueswere compared with reference product values by a univariate
one-way ANOVA, followed by Dunnett’s or Dunnett’s T3
multiple comparisons test as appropriate. Data analysis was
carried out using SPSS software (Version 17.0). Differences
were considered signiﬁcant if p< 0.05.
In order to evaluate the kinetics of the release process of
carbamazepine from the used products, under hydrodynamic
environments generated by the USP paddles method and the
ﬂow-through cell system, dissolution data were ﬁtted to differ-
ent kinetic models: First-order, Higuchi, Korsmeyer-Peppas,
Hixson-Crowell, Makoid-Banakar, Weibull and Logistic.
The model with the highest determination coefﬁcient
(R2adjusted) and the minimum Akaike information criterion
(AIC) was chosen as the best ﬁt (Yuksel et al., 2000). Data
analysis was carried out using the Excel add-in DDSolver pro-
gram (Zhang et al., 2010).
Finally, to evaluate the dissolution proﬁles of the generic
products with respect to the reference product with model-
dependent methods a parameter derived from the best ﬁt mod-
el was compared with a univariate one-way ANOVA followed
by Dunnett’s or Dunnett’s T3 multiple comparisons test. Dif-
ferences were considered signiﬁcant if p< 0.05.3. Results
3.1. Content uniformity and assay
All products met the content uniformity and assay tests spec-
iﬁed in the United States Pharmacopeia. The percentages of
carbamazepine on the content uniformity test ranged from
100.20 to 101.34% and the assay test was between 101.42
and 105.11%.
3.2. Analytical method validation
The mean regression equation from six standard calibration
curves was: y= 0.0435x+ 0.0005. Linear regression was sig-
niﬁcant (R2 = 0.999; p< 0.05). The CI95% estimated for the
value of the intercept was 0.0149 to 0.0158. The highest
CV value was 0.93% for the ﬁve concentration levels
evaluated.
The analytical method validation was done with all prod-
ucts used in the present study however, as an example and in
order that method validation is not the main objective of this
work, only the reference product data are shown. The regres-
sion equation to assess the method linearity was
y= 0.9896x  1.1244 (R2 = 0.998; p< 0.05). The CI95% esti-
mated for the slope was 0.9445 to 1.0346 and 8.4289 to
6.1801 for the intercept. The method accuracy was 98.19%
with a CI95% of 95.39 to 100.99%. The CV value calculated
to assess the method precision was 1.82% and the two-way
ANOVA showed no signiﬁcant differences in drug dissolved
between days and analysts (p> 0.05). All generic products
met national standard validation criteria too.
3.3. Dissolution proﬁles
Carbamazepine dissolution proﬁles obtained with the USP
paddles method and the ﬂow-through cell system are shown
in Fig. 1a and b, respectively.
Figure 1 Dissolution proﬁles of carbamazepine reference (R)
and generic products (AD) with (a) USP paddles method and (b)
ﬂow-through cell system. Mean, n= 12. Error bars were omitted
for clarity. The dotted and dashed lines close to 15 and 60 min
show limits for USP Test 2 and Test 3, respectively.
igure 2 Similarity factor f2 calculated with dissolution data of
eference (R) and generic products (AD).
Table 1 Dissolution parameters calculated with model-inde-
pendent methods. Mean dissolution time (MDT) and dissolu-
tion efﬁciency (DE). Mean ± SEM, n= 12.
Product MDT (min) DE (%)
USP paddles method
R 10.89 ± 0.43 84.54 ± 2.08
A 13.59 ± 0.20a 84.04 ± 0.75
B 11.74 ± 0.08 85.19 ± 0.58
C 11.75 ± 0.18 85.21 ± 0.66
D 11.00 ± 0.28 86.55 ± 0.60
Flow-through cell system
R 15.64 ± 0.15 59.28 ± 1.61
A 22.30 ± 0.18a 42.71 ± 0.41a
B 20.80 ± 0.30a 64.91 ± 0.74a
C 18.35 ± 0.36a 72.80 ± 0.86a
D 18.31 ± 0.12a 70.13 ± 0.75a
a p< 0.05 vs R, Dunnett’s or Dunnett’s T3 multiple comparisons
test.
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the USP Test 3 using the USP paddles method. Taken the
same ofﬁcial dissolution criteria (involving the use of USP
Apparatus 2) products R, C and D met the USP Test 2 and
none of the products met the USP Test 3 using the ﬂow-
through cell system. Dissolution proﬁles of all generic products
were similar to dissolution proﬁle of the reference product
when USP paddles method was used (f2 > 50), while opposite
results were found with the ﬂow-through cell system (f2 < 50),
Fig. 2.
MDT and DE mean values ± standard error medium
(SEM) for products under study in both USP apparatuses
are shown in Table 1.
No signiﬁcant differences were found in data generated by
USP paddles method, excepting MDT of product A
(p< 0.05), while signiﬁcant differences were found in all val-
ues from generic products when compared to the reference
product (p< 0.05) using the ﬂow-through cell system.F
rAccording to the previously established criteria to chose the
best kinetic model the dissolution data of all products with
both USP apparatuses were well ﬁtted by Weibull’s model,
Eq. (2) and Table 2.
F ¼ Fmax 1 e
ðtTiÞb
a
 
ð2Þ
where F is the percentage of drug dissolved at t time, Fmax is
the maximal percentage of drug dissolved at inﬁnite time, a
is the scale parameter, b is the shape parameter and Ti is the
location parameter.
The comparison of the dissolution proﬁles was made ana-
lyzing the derived time parameter (Td) from Weibull’s func-
tion. Td value can be calculated with a and b values and is
equivalent to the MDT value calculated with statistical mo-
ments (Langenbucher, 1972). Signiﬁcant differences were
found in Td values between product A and the reference prod-
uct using the USP paddle method while signiﬁcant differences
Table 2 Criteria used for the selection of the best kinetic model. Mean, n= 12.
Product First-order Higuchi Korsmeyer-Peppas Hixson-Crowell Makoid-Banakar Weibull Logistic
R2adjusted
USP paddles method
R 0.8537 0.8851 0.9361 0.6181 0.9885 0.9996 0.9191
A 0.9398 0.8331 0.9459 0.9646 0.9981 1.0000 0.8911
B 0.9551 0.7336 0.8927 0.9771 0.9961 0.9999 0.9199
C 0.9124 0.7147 0.7956 0.9581 0.9639 0.9997 0.9572
D 0.8647 0.6818 0.7423 0.9276 0.9656 0.9996 0.9305
Flow-through cell system
R 0.9151 0.9023 0.9036 0.8171 0.9837 0.9999 0.9857
A 0.9885 0.9336 0.9732 0.9679 0.9970 1.0000 0.9981
B 0.9525 0.9162 0.9484 0.9844 0.9978 0.9999 0.9863
C 0.9314 0.9107 0.9120 0.9712 0.9912 0.9994 0.9761
D 0.9222 0.8827 0.8901 0.9642 0.9939 0.9996 0.9894
AIC
USP paddles method
R 66.68 70.40 62.89 82.83 43.99 10.48 64.30
A 66.97 83.17 70.93 64.94 30.59 30.88 77.99
B 64.91 88.90 78.88 58.00 39.71 9.90 74.57
C 78.67 93.12 90.24 68.87 70.10 2.57 69.20
D 85.92 96.14 94.74 78.08 70.84 17.35 78.01
Flow-through cell system
R 71.10 74.72 75.48 81.51 54.86 12.59 50.05
A 47.54 69.52 59.39 60.18 33.60 25.70 26.29
B 74.77 82.48 77.41 61.25 38.84 6.16 58.97
C 79.70 83.70 84.22 68.86 57.37 22.15 64.65
D 82.65 87.90 87.96 73.41 53.94 22.65 55.68
Table 3 Weibull’s parameters and Td values derived from the
data adjustment to this kinetic model. Mean, n= 12.
Product a b Ti Fmax Td (±SEM)
USP paddles method
R 2.63 0.43 2.70 114.69 10.22 ± 0.68
A 9.26 0.83 0.16 112.97 14.54 ± 0.36a
B 14.94 1.06 0.65 106.57 12.12 ± 0.09
C 8.57 0.98 3.02 105.89 11.71 ± 0.26
D 210.27 1.99 1.72 106.20 12.64 ± 0.31
Flow-through cell system
R 7.31 0.77 3.54 84.16 16.93 ± 0.30
A 22.09 0.88 3.06 86.32 37.82 ± 2.48a
B 40.67 1.17 2.10 104.66 24.79 ± 0.53a
C 23.58 1.09 2.97 108.07 20.55 ± 0.81a
D 97.49 1.56 1.21 100.26 19.93 ± 0.15a
a p< 0.05 vs R, Dunnett’s or Dunnett’s T3 multiple comparisons
test.
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to the reference product using the ﬂow-through cell system
(p< 0.05), Table 3.
4. Discussion
The dissolution test helps both in characterizing in vitro release
rate and in arriving at single-time-point speciﬁcations that are
appropriate for a conventional (immediate-release) product.
For a dissolution test to be useful as a quality control tool,it must be sensitive to process and/or manufacturing changes.
Uznovic´ et al. (2010) using the dissolution ofﬁcial method with
the USP Apparatus 2, reported drug percent dissolved differ-
ences at 15 and 60 min from two carbamazepine commercial
products and regardless of similar composition of the products
it could be assumed that the technological process of tablet
production signiﬁcantly affected the dissolution rate. In the
present study, carbamazepine ofﬁcial dissolution test was not
discriminating enough, all commercial products used reached
the dissolution criteria (Test 3) and the dissolution proﬁles of
the generic products were similar to the dissolution proﬁle of
the reference product. For different carbamazepine formula-
tions Girad et al. (1996) reported a faster dissolution when
1.0% sodium lauryl sulfate aqueous solution was used together
with the USP paddles method however, simulated intestinal
ﬂuid pH 7.5 was more discriminative between products; Castro
and Jung (2000) demonstrated that the USP dissolution test
cannot be used to predict the bioavailability of commercial
products and Jung et al. (1997) reported that no correlation
was found between in vitro dissolution data, obtained with
the USP paddles method, and in vivo parameters. On the other
hand, Hamlin et al. (1962) hypothesized and later proved that
products differing signiﬁcantly in in vivo performance would
not show in vitro differences if the dissolution test was con-
ducted at a high agitation rate. They concluded that in vitro
test with relatively low agitation rates correlated better with
the in vivo performance of drug products.
In vitro carbamazepine dissolution performance from all
generic products differed from the reference product
(f2 < 50) when the proposed ﬂow-through cell method was
used. Products A and B did not reach the dissolution criteria
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solution rate than the one found with the USP paddles meth-
od. Langenbucher et al. (1989) expressed that this kind of
behavior can be explained by the hydrodynamic conditions
that characterize the ﬂow-through cell system, where no agita-
tion mechanisms exist and the dosage form and the drug par-
ticles are continuously exposed to a uniform laminar ﬂow,
similar to the natural environment of the gastrointestinal tract,
causing different dissolution pattern. We used 16 ml/min as
ﬂow rate because this rate is one of the three suggested by
the European and United States Pharmacopeias (others are 4
and 8 ml/min). Fotaki et al. (2005) reported that the intestinal
ﬂuid axial velocity has been estimated to be approximately of
1.5 cm/min and the ﬂuid ﬂow inside the 22.6 mm cells is 4 cm/
min when the ﬂow rate of dissolution medium is 16 ml/min.
In order to compare the dissolution data of carbamazepine
from the generic products to the reference product, model-
independent parameters MDT and DE were calculated. Car-
dot et al. (2007) mentioned that these parameters have been
proposed as adequate parameters for some IVIVC levels.
IVIVC Level B is based on the comparison of parameters cal-
culated by statistical moments as MDT is (time necessary to
dissolve 63.2% of the drug) and IVIVC Level C requires the
calculation of an in vitro parameter that expresses a global
drug dissolution performance as is the case of DE. This param-
eter relates the area under the curve of the dissolution proﬁle
of the product to the total area of the rectangle formed by
the theoretical dissolution of 100% of the dose and the time
interval of the test. For an in vitro study of carbamazepine con-
trolled-release products Barakat et al. (2009) reported MDT
and DE data using the USP paddles method. Values for Tegre-
tol CR product were 1.91 h and 71.32%, respectively. Disso-
lution studies were conducted with three determinations for a
period of seven h and this was done only for comparative pur-
poses of the proposed formulations.
All products used in the present study were well ﬁtted with
Weibull’s model and comparisons with the Td parameter
showed a better discriminatory capacity of the ﬂow-through
cell system to differentiate between products. Release kinetics
described by Weibull’s equation was reported by Koester
et al. (2004) for dissolution proﬁles of hydroxypropylmethyl-
cellulose matrix tablets containing carbamazepine associated
to b-cyclodextrin.
The use of generic products is important in the health sys-
tem of any country to beneﬁt patients, hospitals and pharma-
ceutical industry. Recently and according to Gidal and
Tomson (2008) the substitution of antiepileptic drugs in pa-
tients with epilepsy has gained increased attention however,
Shaw and Krauss (2008) reported that the FDA has not shown
safety in generic-to-generic switches, which could potentially
cause drug concentration changes of up to 40%. The present
study with the ﬂow-through cell system reveals signiﬁcant dif-
ferences in the rate and extent of carbamazepine dissolution
from Mexican immediate-release generic products used and
this could be replicated in other countries. Previous studies
with the ﬂow-through cell method demonstrated a good
IVIVC between the dissolution proﬁles obtained with the
USP Apparatus 4 and in vivo data, Jinno et al. (2008) for cil-
ostazol immediate-release tablets and Emara et al. (2000) for
vincamine prolonged-release products, both poorly soluble
drugs.As previously mentioned, a signiﬁcant IVIVC has not been
found when the USP paddles method has been used to evalu-
ate the in vitro performance of carbamazepine tablets. On the
other hand, it might be expected that the results obtained with
a more discriminative dissolution method, which has been
proved to simulate more adequately the in vivo performance
of poorly soluble drugs, could better reﬂect the bioavailability
of carbamazepine from immediate-release tablets.
5. Conclusion
Data with the ﬂow-through cell system conﬁrm that the disso-
lution method proposed has a greater discriminating ability
than the USP paddles method to identify signiﬁcant differences
between rate and extent dissolution of carbamazepine immedi-
ate-release tablets. It is possible to mention that carbamaze-
pine products with differences in dissolution performance are
candidates to show bioavailability differences so it is suggested
to evaluate their in vivo performance to conﬁrm the predict-
ability of the in vitro proposed method.
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